Comparison of insurance coverage of tobacco cessation pharmacotherapies in five countries from the Organisation for Economic Co-operation and Development;Comparaison des systèmes de couverture assurantielle des traitements pharmacologiques d'aide au sevrage tabagique dans cinq pays de l'Organisation de Coopération et de Développement Économiques

Revue d'Epidemiologie et de Sante Publique

Volumn 53, Issue 5, 2005, Pages 535-548

  Le Faou, A L ^a,b   Scemama, O ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

Bupropion SR; Health; Insurance; Insurance coverage; Nicotine; Smoking cessation; Tobacco control

Indexed keywords

AMFEBUTAMONE;

ARTICLE; AUSTRALIA; CANADA; FINANCIAL MANAGEMENT; FOLLOW UP; FRANCE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH PRACTITIONER; HUMAN; INSURANCE; NEW ZEALAND; PHYSICIAN; SMOKING CESSATION; TOBACCO DEPENDENCE; UNITED KINGDOM; UNITED STATES;

EID: 27844594355     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0398-7620(05)84730-3     Document Type: Article

References (62)

1. Hill C, Laplanche A. Tabagisme et mortalité: aspects épidémiologiques. BEH 2003; 22-23: 98-100.
2. Haut Comité de la Santé Publique. La santé en France. Paris: Éditions HCSP, 2002: 1-412.
3. Woolacott N, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1-245.
4. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996; 275: 1247-51.
5. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999; 354: 210-5.
6. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19: 125-52.
7. World Health Organization. Regulation of nicotine replacement therapies: an expert consensus. Copenhagen: WHO, Regional Office for Europe, 2001: 42 p.
8. Agence Nationale d'Accréditation et d'Évaluation en Santé. Arrêt de la consommation du tabac - Texte des recommandations - Recommandations professionnelles. In: Conférence de consensus, Hôpital Pitié-Salpêtrière, 8 et 9 octobre. Paris: ANAES, 1998: 26 p.
9. Direction Générale de la Santé. Cancer: une mobilisation nationale, tous ensemble. Paris: Ministère de la Santé, 2003: 39 p.
10. Department of Health. Smoking Kills. A white paper on tobacco. London: Stationery Office, 1998. http:// www.archive.official-documents.co.uk/document/ cm41/4177/4177.htm
11. NHS executive. Health Service Circular 1999/087. New NHS cessation services. London: NHS, 1999.
12. Bates C, McNeill AD, Owen L. Smoking cessation services. Implementing the NHS National Plan. London: Action on Smoking and Health, 2000.
13. Coleman T, West R. Newly available treatments for nicotine addiction. Smokers wanting help with stopping now have effective treatment options. BMJ 2001; 322: 1076-7.
14. Department of Health. NHS smoking cessation services - Service and monitoring guidance 2001/02. London: Stationery Office, 2001: 30 p. http:// www.dh.gov.uk/assetRoot/04/07/81/16/04078116.pdf
15. Armstrong M, McNeil A, McRobbie H. Improving local access to smoking cessation therapies by using Patient Group Directions. London: Pharmacy Health-Link, 2003.
16. New Zealand Ministry of Health Manatu Hauora. Tobacco Action Plan. Wellington: Ministry of Health, 2000.
17. Ministerial Council on Drug Strategy. National Tobacco Strategy 1999 to 2002-03: A framework for action. Canberra: Commonwealth Department of Health and Aged Care, 1999.
18. Miller M, Wood L. Smoking cessation interventions: review of evidence and implications for best practice in healthcare settings. Canberra: Commonwealth Department of Health and Ageing, 2001.
19. er octobre 2000 au 31 janvier 2002. Montréal: Régie de l'assurance maladie Québec, 2002.
20. Régie de l'assurance maladie Québec. Le régime public - Les médicaments couverts: les produits anti-tabac. http://www.ramq.gouv.qc.ca: consulté le 9/ 02/2004.
21. Chambaretaud S, Lequet-Slama D, Rodwin VG. Couverture maladie et organisation des soins aux États-Unis. Paris: Direction de la Recherche, des Études, de l'Évaluation et des Statistiques, 2001; 119: 1-11.
22. Centers for Disease Control and Prevention. State Medicaid Coverage for Tobacco-Dependence Treatments - United States 1994-2002. MMWR 2004; 53: 54-7.
23. Centers for Disease Control and Prevention. State Medicaid Coverage for Tobacco-Dependence Treatments - United States 1994-2001. MMWR 2003; 52: 496-500.
24. Professional Assisted Cessation Therapy (PACT). Reimbursement for smoking cessation therapy: A Healthcare Practitioner's Guide. Hackensack, NJ: RSi Communications, 2002: 28 p. http://www.endsmoking.org/resources/ reimbursementguide/pdf/reimbursementguide-2nd-edition.pdf
25. McPhillips-Tangum C, Bocchino C, Carreon R, Erceg C, Rehm B. Addressing tobacco in managed care: result of the 2002 survey. Preventing Chronic Desease [serial online] 2004 Oct; URL: http:// www.cdc.gov/pcd/issues/2004/oct/pdf/ 04_0021.pd
26. McPhillips-Tangum C. Results from the first annual survey on addressing tobacco in managed care. Tob Control 1998; 7 Suppl: S11-3.
27. McPhillips-Tangum C, Cahill A, Bocchino C, Cutler C. Addressing tobacco in managed care: results of the 2000 survey. Prev Med Manag Care 2002; 3: 85-94.
28. Michigan Association of Health Plans. Michigan insurers' tobacco cessation benefits. http://www.mahp.org/ MAHP%20Foundation/smoking/benefitsgrid. htm: consulté le 9 février 2004.
29. World Health Organization Regional Office for Europe. The European report on tobacco control policy. Copenhagen: World Health Organization, 2002. http://www.euro.who.int/Document/E74573.pdf.
30. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics 1997; 11: 538-49.
31. US Preventive Services Task Force. Guide to clinical preventive services. Rockville, MD: AHRQ, 1996. http://www.ahrq.gov/clinic/uspstfab.htm.
32. Coffield AB, Maciosek MV, McGinnis JM Harris JT, Caldwell MB, Teutsch SM, et al. Priorities among recommended clinical preventive services. Am J Prev Med 2001; 21: 1-9.
33. Chang CF. A critical review of the arguments for insurance coverage for smoking-cessation therapies. Manag Care 2001; 10: 62-5.
34. Cox JL, McKenna JP. Nicotine gum: does providing it free in a smoking cessation program alter success rates? J Fam Pract 1990; 31: 278-80.
35. Hughes JR, Wadland WC, Fenwick JW, Lewis J, Bickel WK. Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. Prev Med 1991; 20: 486-96.
36. Schauffler HH, McMenamin S, Olson K, Boyce-Smith G, Rideout JA, Kamil J. Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial. Tob Control 2001; 10: 175-80.
37. Boyle RG, Solberg LI, Magnan S, Davidson G, Alesci NL. Does insurance coverage for drug therapy affect smoking cessation? Health Aff (Millwood) 2002; 21: 162-8.
38. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997; 96: 1089-96.
39. Solanki G, Schauffler HH. Cost-sharing and the utilization of clinical preventive services. Am J Prev Med 1999; 17: 127-33.
40. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1999.
41. Schauffler HH. Defining benefits and payment for smoking cessation treatments. Tob Control 1997; 6: S81-5.
42. Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002; 22: S26-37.
43. Harris JR, Schauffler HH, Milstein A, Powers P, Hopkins DP. Expanding health insurance coverage for smoking cessation treatments: experience of the Pacific Business Group on Health. Am J Health Promot 2001; 15: 350-6.
44. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997; 278: 1759-66.
45. Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90: 31-42.
46. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994; 271: 589-94.
47. Yudkin PL, Jones L, Lancaster T, Fowler GH. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial. Br J Gen Pract 1996; 46: 145-8.
48. Schauffler HH. Coverage for tobacco dependence treatments: results of a randomized control trial in California HMOs. In: Third Annual Conference on Addressing Tobacco in Managed Care. Atlanta, GA: February 2000.
49. Tauras JA, Chaloupka FJ. The demand for nicotine replacement therapies. Nicotine Tob Res 2003; 5: 237-43.
50. Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998; 339: 673-9.
51. Ockene JK. Physician-delivered interventions for smoking cessation: strategies for increasing effectiveness. Prev Med 1987; 16: 723-37.
52. McEwen A, West R. Smoking cessation activities by general practitioners and practice nurses. Tob Control 2001; 10: 27-32.
53. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking Cessation: information for specialists. In: Clinical Practice Guideline No 18. (AHCPR Publication No 96-0694). Rockville, Maryland: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996.
54. Agence Française de Sécurité Sanitaire des Produits de Santé. Recommandation de Bonne Pratique - Les stratégies thérapeutiques médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac - Recommandations. Saint-Denis: AFSSAPS, mai 2003: 39 p.
55. Katz DA, Muehlenbruch DR, Brown RL, Fiore MC, Baker TB. Effectiveness of implementing the Agency for Healthcare Research and Quality smoking cessation clinical practice guideline: a randomized, controlled trial. J Natl Cancer Inst 2004; 96: 594-603.
56. Helgason AR, Lund KE. General practitioners' perceived barriers to smoking cessation-results from four Nordic countries. Scand J Public Health 2002; 30: 141-7.
57. Schauffler HH, Rodriguez T. Availability and utilization of health promotion programs and satisfaction with health plan. Med Care 1994; 32: 1182-96.
58. Solberg LI, Davidson G, Alesci NL, Boyle RG, Magnan S. Physician smoking-cessation actions: are they dependent on insurance coverage or on patients? Am J Prev Med 2002; 23: 160-5.
59. Caisse Nationale d'Assurance Maladie des Travailleurs Salariés. Prise en charge gratuite des substituts nicotiniques dans les centres d'examens de santé de l'Assurance Maladie, http://www.ameli.fr/174/ DOC/783/cp.htm
60. Direction de la Santé. Sevrage tabagique: guide méthodologique 2003. Bagnolet: Caisse Centrale de la Mutualité Sociale Agricole, 2003.
61. Décret 2002-594 du 22 avril 2002 relatif à la liste des affections comportant un traitement prolongé et une thérapeutique particulièrement coûteuses et modifiant le code de la Sécurité sociale. Paris: Journal Officiel de la République Française, 27 avril 2002.
62. US Department of Health and Human Services. Healthy people 2010, 2nd ed. With Understanding and Improving Health and Objectives for Improving Health (2 vols). Washington, DC: US Department of Health and Human Services, 2000 http://www.healthypeople.gov/document/tableofcontents.htm